Last deck

Question 1

Preferred conditioning for CNS lymphoma

Answer 1

*Thiotepa based
TBC (thiotepa, busulfan, and cyclophosphamide) or TT-BCNU (thiotepa and carmustine)

Question 1

Prophylaxis antepartum and postpartum for prothrombin gene mutation

Answer 1

Nothing

Question 2

antepartum and postpartum prophylaxis for protein C and S deficiency

Answer 2

Only postpartum and only if family history of VTE

Question 3

antepartum and postpartum prophylaxis for antithrombin deficiency

Answer 3

• only if family history
  IF family history, then antepartum and postpartum

Question 4

Least important HLA antigen

Answer 4

DQB1

Question 5

Inv 16 associated gene

Answer 5

CBFB

Question 6

Treatment of ciclic neutropenia

Answer 6

GCSF

Question 7

Castleman’s disease second line

Answer 7

Rituximab

Question 8

preferred management of unicentric castleman’s

Answer 8

Complete surgical resection

Question 9

Rasburicase mechanism

Answer 9

Recombinant version of urate oxidase, an enzyme that metabolizes uric acid to allantoin.

Question 10

Management of patient off TKI in CML with detectable BCR/ABL PCR

Answer 10

Repeat in 2 weeks, if still detectable, resume TKI

Question 11

Universal blood donor type

Answer 11

O negative

Question 12

HELLP mgmt

Answer 12

• control BP
• magnesium
  *noo role for steroids or PLEX

Question 13

VWF and pregnancy goals

Answer 13

• Levels of VWF and factor VIII be maintained at ≥50 IU/dL during delivery and for at least three to five days after delivery
• Aim for VWF and Factor VIII close to 80-100% at time of delivery

Question 14

RF’s for CNS involvement in ALL

Answer 14

??

Question 15

Initial management of acquired PRCA

Answer 15

• transfuse as needed
• treat underlying illness
• discontinue any implicated drugs

Question 16

Management of PRCA that doesn’t improve with initial measures

Answer 16

• Cyclosporine
• steroids
  IF parvovirus associated, IVIG

Question 17

Differentiation syndrome context + presentation

Answer 17

• Typically in APML
• fever + weight gain + hypotension + pulmonary infiltrates

Question 18

CAR-T approved for ALL

Answer 18

• brexi-cell
• tisa-cel

Question 19

Gene mutation associated with congenital AML?

Answer 19

KMT2A

Question 20

Definitive proof of transfusion associated GVHD

Answer 20

White blood cell chimerism (Different HLA phenotype in circulating lymphocytes compared with the HLA phenotype of host tissue cells)